Description

Retosiban is a selective oxytocin receptor antagonist, representing a significant advancement in the field of reproductive medicine and tocolytic research. Its primary value lies in its targeted mechanism of action, offering a potential therapeutic pathway for managing preterm labor by inhibiting uterine contractions. This compound is of critical interest to pharmaceutical R&D teams, contract research organizations (CROs), and academic institutions focused on developing novel treatments in obstetrics and gynecology. The material is supplied as a high-purity reference standard and active pharmaceutical ingredient (API) intermediate for research and development purposes.

Application

• Pharmaceutical R&D: Serves as a key reference standard and intermediate in the research and development of novel tocolytic agents for preterm labor.
• Mechanistic Studies: Used in in vitro and in vivo studies to investigate the role of oxytocin receptors in uterine physiology and pathophysiology.
• Preclinical Development: Essential for pharmacokinetic, pharmacodynamic, and toxicology studies during the drug discovery pipeline for obstetric indications.
• Biochemical Assays: Employed as a selective ligand in receptor binding assays and high-throughput screening (HTS) to identify and characterize new chemical entities.
• Academic Research: Utilized by university laboratories for fundamental research into parturition, hormone signaling, and reproductive biology.
• Process Chemistry: Acts as a critical intermediate for process chemists optimizing synthetic routes for scale-up and manufacturing of the API.

Basic Information

Product Name	Retosiban
CAS No.	820957-38-8
Molecular Formula	C₂₃H₃₀N₄O₃S
Molecular Weight	442.57 g/mol
Synonyms	Retosiban; GSK 221149; GSK-221149; GSK221149; 1-[(7,7-Dimethyl-2,5-dioxo-3-thia-1,6-diazabicyclo[3.2.0]hept-6-yl)carbonyl]-4-[4-(2-methyl-1H-imidazol-1-yl)phenyl]piperazine; (1S,5S,6S)-6-({4-[4-(2-Methyl-1H-imidazol-1-yl)phenyl]piperazin-1-yl}carbonyl)-3-thia-1,6-diazabicyclo[3.2.0]heptane-2,5-dione 7,7-dioxide
EINECS	Contact for details

Quality Control

Our Retosiban is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing, including HPLC for purity, chiral analysis, and identity confirmation (IR, NMR, MS) to ensure it meets the stringent requirements for pharmaceutical research. We provide full traceability and Certificates of Analysis (COA) are available for every shipment, detailing all critical quality attributes. Our commitment is to supply material that supports robust and reproducible scientific outcomes.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature (15-25°C) in a dry environment. For long-term storage, consider storing desiccated at -20°C. Keep the container tightly sealed to protect from moisture.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Purity (HPLC)	≥ 98.0%
Chiral Purity	≥ 99.0% ee
Water Content (KF)	≤ 0.5%
Residual Solvents (GC)	Complies with ICH Q3C
Heavy Metals	< 10 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.